The NEVOLUTION Study: An Open Label, Single-arm, Phase II Study of Neoadjuvant Nivolumab in Locally Advanced Upper Tract Urothelial Carcinoma
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- Acronyms NEVOLUTION Study
- 21 Dec 2021 New trial record